PT1782825E - Tratamento de doenças de armazenanto de glicogénio tipo ii - Google Patents

Tratamento de doenças de armazenanto de glicogénio tipo ii Download PDF

Info

Publication number
PT1782825E
PT1782825E PT70010913T PT07001091T PT1782825E PT 1782825 E PT1782825 E PT 1782825E PT 70010913 T PT70010913 T PT 70010913T PT 07001091 T PT07001091 T PT 07001091T PT 1782825 E PT1782825 E PT 1782825E
Authority
PT
Portugal
Prior art keywords
treatment
glycogen storage
storage diseases
diseases type
type
Prior art date
Application number
PT70010913T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1782825(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Publication of PT1782825E publication Critical patent/PT1782825E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT70010913T 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii PT1782825E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18

Publications (1)

Publication Number Publication Date
PT1782825E true PT1782825E (pt) 2014-11-04

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
PT16178390T PT3108895T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT70010913T PT1782825E (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii
PT181947714T PT3449934T (pt) 2000-07-18 2001-07-10 Tratamento de doença de armazenanto de glicogénio tipo ii
PT01951000T PT1301201E (pt) 2000-07-18 2001-07-10 Tratamento da doença de armazenamento de glicogénio tipo ii
PT141678821T PT2767291T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT16178390T PT3108895T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT181947714T PT3449934T (pt) 2000-07-18 2001-07-10 Tratamento de doença de armazenanto de glicogénio tipo ii
PT01951000T PT1301201E (pt) 2000-07-18 2001-07-10 Tratamento da doença de armazenamento de glicogénio tipo ii
PT141678821T PT2767291T (pt) 2000-07-18 2001-07-10 Tratamento de doenças de armazenanto de glicogénio tipo ii

Country Status (18)

Country Link
US (10) US7056712B2 (pt)
EP (4) EP3449934B1 (pt)
JP (10) JP5113312B2 (pt)
AT (1) ATE355075T1 (pt)
AU (3) AU2001271941B2 (pt)
BR (1) BR0113006A (pt)
CA (1) CA2416492C (pt)
CY (2) CY1120977T1 (pt)
DE (1) DE60126947T2 (pt)
DK (5) DK1782825T3 (pt)
ES (5) ES2799882T3 (pt)
HK (3) HK1054690A1 (pt)
LT (3) LT3108895T (pt)
MX (1) MXPA03000474A (pt)
PT (5) PT3108895T (pt)
SI (3) SI3449934T1 (pt)
TW (1) TWI280882B (pt)
WO (1) WO2002005841A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2445577C (en) * 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
WO2010005565A2 (en) 2008-07-08 2010-01-14 Duke University Method of treating glycogen storage disease
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
CN115120745A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经***转移
FI3201320T3 (fi) 2014-09-30 2024-01-08 Amicus Therapeutics Inc Erittäin tehokas hapan alfa-glukosidaasi parannetuilla hiilihydraateilla
JP6821192B2 (ja) * 2015-05-07 2021-01-27 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
MA44747A (fr) * 2015-08-31 2019-03-06 Univ Duke Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR20220145918A (ko) 2016-03-30 2022-10-31 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
IL139616A0 (en) 1998-05-13 2002-02-10 Harbor Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
KR20010101131A (ko) * 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
ES2799882T3 (es) * 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2005078077A2 (en) * 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
SI3108895T1 (sl) 2019-01-31
JP2020019822A (ja) 2020-02-06
EP2767291B1 (en) 2016-09-14
BR0113006A (pt) 2004-10-19
US9907839B2 (en) 2018-03-06
JP5792774B2 (ja) 2015-10-14
HK1103363A1 (en) 2007-12-21
DK1782825T3 (da) 2014-11-03
MXPA03000474A (es) 2003-10-06
US20020110551A1 (en) 2002-08-15
ATE355075T1 (de) 2006-03-15
DK1301201T3 (da) 2007-04-02
LT2767291T (lt) 2016-11-25
EP1301201A1 (en) 2003-04-16
PT3449934T (pt) 2020-06-25
US20150004152A1 (en) 2015-01-01
US20050123531A1 (en) 2005-06-09
US8900552B2 (en) 2014-12-02
JP2014185187A (ja) 2014-10-02
JP2016056206A (ja) 2016-04-21
EP3108895B1 (en) 2018-09-19
DK3449934T3 (da) 2020-06-29
CY1123084T1 (el) 2021-10-29
ES2523024T3 (es) 2014-11-20
WO2002005841A1 (en) 2002-01-24
JP2012006953A (ja) 2012-01-12
ES2700865T3 (es) 2019-02-19
US20210169996A1 (en) 2021-06-10
US20130195834A1 (en) 2013-08-01
JP2008081507A (ja) 2008-04-10
EP3449934A1 (en) 2019-03-06
DK2767291T3 (en) 2016-12-05
JP2013231081A (ja) 2013-11-14
ES2277931T3 (es) 2007-08-01
JP6163216B2 (ja) 2017-07-12
US20080175833A1 (en) 2008-07-24
EP2767291A2 (en) 2014-08-20
EP3108895A1 (en) 2016-12-28
PT3108895T (pt) 2018-12-18
US20120058132A1 (en) 2012-03-08
DE60126947D1 (de) 2007-04-12
US20180185457A1 (en) 2018-07-05
US9370556B2 (en) 2016-06-21
ES2799882T3 (es) 2020-12-22
EP1301201B1 (en) 2007-02-28
DK3108895T3 (en) 2018-11-26
CA2416492C (en) 2008-04-29
ES2599401T3 (es) 2017-02-01
US7056712B2 (en) 2006-06-06
US20100254966A1 (en) 2010-10-07
SI2767291T1 (sl) 2016-11-30
AU2001271941B2 (en) 2007-03-01
SI3449934T1 (sl) 2020-09-30
AU2010200487A1 (en) 2010-03-04
US20160184410A1 (en) 2016-06-30
JP5113312B2 (ja) 2013-01-09
AU7194101A (en) 2002-01-30
EP3449934B1 (en) 2020-05-20
DE60126947T2 (de) 2007-10-31
CY1120977T1 (el) 2019-12-11
HK1054690A1 (en) 2003-12-12
CA2416492A1 (en) 2002-01-24
JP2004503598A (ja) 2004-02-05
PT2767291T (pt) 2016-10-25
JP2018002749A (ja) 2018-01-11
LT3108895T (lt) 2018-11-26
HK1197656A1 (zh) 2015-02-06
JP2017137357A (ja) 2017-08-10
LT3449934T (lt) 2020-08-10
EP2767291A3 (en) 2014-10-08
US10792341B2 (en) 2020-10-06
PT1301201E (pt) 2007-03-30
JP2018199721A (ja) 2018-12-20
TWI280882B (en) 2007-05-11

Similar Documents

Publication Publication Date Title
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
TW200500358A (en) Compounds
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
EP1782825A3 (en) Treatment of glycogen storage diseases type II